CLINICAL_TRIALS
trial_result
· 2010-06-10
Clinical Trial Update: Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease [Phase 4]
Summary
A Phase 4 placebo-controlled trial is evaluating Lovaza (omega-3-acid ethyl esters) as a treatment for non-alcoholic fatty liver disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Huntington Medical Research Institutes | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 4 | Status: UNKNOWN